[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335509-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335509-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genomic-immunologic-and-prognostic-associations-of-trop2-tacstd2-expression-in-solid-tumors","Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","","TROP2 (TACSTD2) expression correlates with decreased overall survival in some solid tumors, and the TROP2-targeting ADC sacituzumab govitecan is approved for breast and urothelial cancers. This study characterizes the multiomic landscape linked to TACSTD2 gene expression across multiple tumor types to determine who may benefit. Tumors were stratified by TACSTD2 quartiles and assessed using sequencing and immunohistochemistry, with survival derived from insurance claims and Kaplan-Meier analyses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genomic-immunologic-and-prognostic-associations-of-trop2-tacstd2-expression-in-solid-tumors/335509/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genomic-immunologic-and-prognostic-associations-of-trop2-tacstd2-expression-in-solid-tumors/335509.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of analyzing TACSTD2 expression in solid tumors?","Question",{"text":63,"@type":64},"To explore the multiomic landscape associated with TACSTD2 gene expression across solid tumors and identify patients most likely to benefit from TROP2-targeting strategies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were tumors stratified in the study?",{"text":68,"@type":64},"Breast, colorectal, hepatocellular, pancreatic, and urothelial tumors were stratified into quartiles by TACSTD2 gene expression.",{"name":70,"@type":61,"acceptedAnswer":71},"What prognostic and immune associations were found for TACSTD2-high tumors?",{"text":72,"@type":64},"TACSTD2-high tumors were associated with pathogenic driver alterations, greater immune cell infiltration, higher T-cell inflammation scores, and significantly shorter overall survival in key subsets, including breast, colorectal (microsatellite stable), and pancreatic (KRAS-mutant) cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335509,1790095752,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors  \nDan Morgenstern-Kaplan1,, Samuel A. Kareff1,, Asaad Trabolsi1,, Estelamari Rodriguez1,, Harris Krause2,, Jennifer R. Ribeiro2,, Heng Tan1, Emmanuel S. Antonarakis3,,  \nEmil Lou3,, Misako Nagasaka4,, Sandra Algaze5,, Heinz-Josef Lenz5,, Stephen V. Liu6, Balazs Halmos7,, Dave S. B. Hoon8,, Andreas Seeber9,, Patrick C. Ma10, Wafik S. El-Deiry11,, Ari M. Vanderwalde2,, Gilberto Lopes*, 1,  \n1Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, FL 33131, United States,  \n2Caris Life Sciences, Phoenix, AZ 85040, United States,  \n3University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, United States,  \n4Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange, CA 92617, United States,  \n5Division of Medical Oncology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States, 6Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, United States, 7Montefiore Einstein Comprehensive Cancer Center, Bronx, NY 10461, United States,  \n8Saint John’s Cancer Institute, Providence Health System, Santa Monica, CA 90404, United States, 9Tyrolean Cancer Research Institute, Innsbruck Medical University, Innsbruck 6020, Austria, 10Division of Hematology/Oncology, Penn State Cancer Institute, Hershey, PA 17033, United States,  \n11Legorreta Cancer Center, Warren Alpert Medical School of Brown University, Providence, RI 02912, United States  \n* Corresponding author: Gilberto Lopes, MD, MBA, Sylvester Comprehensive Cancer Center at the University of Miami, 1240 NW 14th Street, Suite 650L, Miami, FL 33131, USA ([glopes@med.miami.edu](glopes@med.miami.edu)) .  \nAbstract  \nBackground: TROP2 ( TACSTD2) expression is associated with decreased overall survival (OS) in some solid tumors, and the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan has been approved in breast and urothelial carcinomas. We aimed to explore the multiomic landscape associated with TACSTD2 gene expression in various solid tumors to identify patients most likely to benefit from this approach. Methods: Breast (N = 11 246), colorectal (N = 15 425), hepatocellular (N = 433), pancreatic (N = 5488), and urothelial (N = 4125) tumors were stratified into quartiles by TACSTD2 gene expression, analyzed by next-generation DNA sequencing, whole transcriptome sequencing, and immunohistochemistry at Caris Life Sciences (Phoenix, AZ) . Survival data were obtained from insurance claims, and Kaplan-Meier estimates were calculated for molecularly defined cohorts.  \nResults: Several pathogenic mutations were associated with TACSTD2-high tumors, including TP53 in breast, colorectal (CRC), pancreatic, and hepatocellular cancers; KRAS in pancreatic and CRC cancers; ARID1A and FGFR3 in urothelial cancer; and CTNNB1 in hepatocellular cancer. TACSTD2-low breast tumors were enriched for copy number amplifications in CCND1 and FGF/R family member genes. TACSTD2 high was generally associated with more immune cell infiltration and greater T-cell inflammation scores. Patients with TACSTD2-high breast, CRC, and pancreatic cancers demonstrated a significantly shorter OS than TACSTD2-low tumors. This was restricted to CRC with microsatellite stable tumors and patients with pancreatic cancer with KRAS-mutant tumors. Patients with breast cancer with TACSTD2-high tumors also experienced significantly worse OS following immune checkpoint inhibitors.  \nConclusions: TACSTD2 expression is associated with key driver alterations and a more active immune microenvironment, suggesting possible combinatorial strategies with TROP2-targeting ADCs plus immunotherapy in various solid tumors.  \nKey words: TROP2; precision oncology; targeted therapy; tumor genetics.  \nImplications for Practice  \nThis stud","cbCaivEeReQP4PTt","https://ap.wps.com/l/cbCaivEeReQP4PTt","pdf",15203994,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Implications for Practice\n# Introduction\n## TROP2/TACSTD2 in biology and cancer signaling\n# Received and publication details","[{\"question\":\"What was the purpose of analyzing TACSTD2 expression in solid tumors?\",\"answer\":\"To explore the multiomic landscape associated with TACSTD2 gene expression across solid tumors and identify patients most likely to benefit from TROP2-targeting strategies.\"},{\"question\":\"How were tumors stratified in the study?\",\"answer\":\"Breast, colorectal, hepatocellular, pancreatic, and urothelial tumors were stratified into quartiles by TACSTD2 gene expression.\"},{\"question\":\"What prognostic and immune associations were found for TACSTD2-high tumors?\",\"answer\":\"TACSTD2-high tumors were associated with pathogenic driver alterations, greater immune cell infiltration, higher T-cell inflammation scores, and significantly shorter overall survival in key subsets, including breast, colorectal (microsatellite stable), and pancreatic (KRAS-mutant) cancers.\"}]","Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors | PDF",1790011214]